US6410520B2 - Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate - Google Patents
Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate Download PDFInfo
- Publication number
- US6410520B2 US6410520B2 US09/771,825 US77182501A US6410520B2 US 6410520 B2 US6410520 B2 US 6410520B2 US 77182501 A US77182501 A US 77182501A US 6410520 B2 US6410520 B2 US 6410520B2
- Authority
- US
- United States
- Prior art keywords
- monohydrate
- hemipentahydrate
- pyridyl
- aqueous solution
- bisphosphonic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- IIDJRNMFWXDHID-UHFFFAOYSA-N O=P(O)(O)C(O)(CC1=CC=CN=C1)P(=O)(O)O Chemical compound O=P(O)(O)C(O)(CC1=CC=CN=C1)P(=O)(O)O IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-M O=P([O-])(O)C(O)(CC1=CN=CC=C1)P(=O)(O)O.[Na+] Chemical compound O=P([O-])(O)C(O)(CC1=CN=CC=C1)P(=O)(O)O.[Na+] IIDJRNMFWXDHID-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Definitions
- the present invention relates to 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium hemipentahydrate and monohydrate, compositions containing said hemipentahydrate and/or monohydrate and methods of selective crystallization of the hemipentahydrate or monohydrate.
- Bisphosphonates such as 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid (RISEDRONATE) have been proposed for use in the treatment of diseases of bone and calcium metabolism.
- diseases include osteoporosis, hyperparathyroidism, hypercalcemia of malignancy, ostolytic bone metastases, myosistis ossifcans progressiva, calcinoisis universalis, arthritis, neuritis, bursitis, tendonitis and other inflammatory conditions.
- Paget's disease and heterotropic ossification are currently successfully treated with both EHDP (ethane-1-hydroxy-1,1-diphosphonic acid) and RISEDRONATE.
- the bisphosphonates tend to inhibit the resorption of bone tissue, which is beneficial to patients suffering from excessive bone loss.
- all bisphosphonates do not exhibit the same degree of biological activity.
- Some bisphosphonates have serious drawbacks with respect to the degree of toxicity in animals and the tolerability or negative side effects in humans.
- the salt and hydrate forms of bisphosphonates alter both their solubility and their bioavailability.
- the present invention discloses 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium hemipentahydrate and monohydrate, compositions containing said hemipentahydrate and/or monohydrate and methods of selective crystallization of the hemipentahydrate or monohydrate.
- the temperature of nucleation and the rate of crystallization are the critical variables that control the ratio of hydrates formed.
- the present invention is directed to a 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium hemipentahydrate and monohydrate and compositions containing said hemipentahydrate and monohydrate.
- a novel process is also disclosed for the selective crystallization of the geminal bisphosphonate, risedronate sodium, 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate and as the monohydrate.
- risedronate sodium the mono sodium salt of risedronate, exists in three crystalline hydration states: anhydrous, mono and hemipentahydrate.
- the monohydrate and hemipentahydrate are preferred.
- the hemipentahydrate is the thermodynamically preferred crystalline form under typical processing conditions based on the observation that monohydrate crystals converted to the hemipentahydrate form.
- the monohydrate is by weight of water from about 5.0% to about 7.1%, more preferably from about 5.6% to about 6.5% and most preferably about 5.6%.
- the monohydrate is further characterized by single crystal X-ray crystallography, and thermogravimetric analysis.
- the monohydrate form also exhibits identifiable signatures when examined by X-ray powder diffraction, differential scanning calorimetry, Fourier transform infrared spectroscopy or near infrared spectroscopy.
- the hemipentahydrate is by weight of water from about 11.9% to about 13.9%, more preferably from about 12.5% to about 13.2% and most preferably about 12.9%.
- the hemipentahydrate is further characterized by single crystal X-ray crystallography, and thermogravimetric analysis.
- the hemipentahydrate form also exhibits identifiable signatures when examined by X-ray powder diffraction, differential scanning calorimetry, Fourier transform infrared spectroscopy or near infrared spectroscopy.
- the temperature of nucleation and the rate of crystallization are the critical variables that control the ratio of hydrates formed.
- the nucleation temperature can be controlled by controlling the ratio of water to solute, the solution temperature, and the ratio of organic solvent to water.
- the risedronate sodium hemipentahydrate is the thermodynamically favored form under the typical processing conditions described.
- Compositions comprise by weight of risedronate sodium hydrate from about 50% to about 100%, more preferably from about 80% to about 100%, most preferably from about 90% to about 100% risedronate sodium hemipentahydrate and from about 50% to about 0%, more preferably from about 20% to about 0%, most preferably from about 10% to about 0% risedronate sodium monohydrate.
- compositions comprise by weight of risedronate sodium hydrate from about 50% to about 99%, more preferably from about 80% to about 99%, most preferably from about 95% to about 99% risedronate sodium monohydrate and from about 50% to about 1%, more preferably from about 20% to about 1%, most preferably from about 5% to about 1% risedronate sodium hemipentahydrate.
- the invention further comprises pharmaceutical compositions containing the hemipentahydrate and monohydrate compounds.
- risedronate denotes 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid and has the following structure:
- solvent is a substance capable of dissolving another substance to form a uniform solution.
- the solvent may either be polar or non-polar.
- Solvents are selected from the group consisting of alcohols, esters, ethers, ketones, amides, and nitriles. Most preferred is isopropanol.
- the process according to the present invention is characterized in that the process described herein is readily adapted to industrial production.
- the following non-limiting examples illustrate the processes of the present invention.
- the extent of hydration 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium can be controlled by varying the crystallization parameters to control the temperature of nucleation and rate of crystallization.
- the ratio of hemipentahydrate to monohydrate crystal forms in the product can be effectively controlled by varying the water to 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium ratio and the isopropanol to water ratio as well as the temperature (see below).
- An aqueous solution of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium at 0-75° C., preferably 25-75° C., more preferably 45-75° C. will selectively yield either the monohydrate or the hemipentahydrate crystal forms depending upon the conditions of crystallization.
- the temperature of nucleation and the rate of crystallization governs the hydrate, varying the ratio of water: isopropanol and varying temperature and cooling ramp of the aqueous solution control the ratios of the hydration states formed.
- Table 1 shows eight examples of reaction conditions which selectively produce 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium containing varying hemipenta to monohydrate ratios.
- the theoretical moisture level for the monohydrate is 5.6% and for the hemipentahydrate is 12.9%.
- Conditions leading to nucleation between 25-70° C., preferably 50-70° C. with a cooling ramp of 0.1-5° C. per minute, preferably 0.1-2° C. per minute produce the hemipentahydrate.
- the hemipentahydrate is formed by suspending 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid n water at about 60° C., adjusting the pH to 4.7-5.0 with sodium hydroxide, adding isopropanol to the resulting solution, cooling the suspension and collecting the product by filtration.
- Conditions leading to nucleation above 45° C., preferably above 55° C. with appropriate time at temperature and without a cooling ramp or with a rapid quench produce the monohydrate. Maintaining the aqueous solution of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium at 70° C., the monohydrate slowly crystallizes and is isolated by filtration of the crystals from the hot solution. Conversely, quenching of the 70° C. aqueous solution directly into 0° C. isopropanol also yields the crystalline monohydrate.
- the compounds made herein may be used in pharmaceutical compositions.
- pharmaceutical composition means a dosage form comprised of a safe and effective amount of an active ingredient and pharmaceutically-acceptable excipients.
- the pharmaceutical compositions described herein are comprised of from about, 0.1% to about 99%, preferably from about 0.5% to about 95% of a bisphosphonate active ingredient, and from about 1% to about 99.9%, preferably from 5.00% to about 99.90% of pharmaceutically-acceptable excipients.
- an oral composition comprises, preferably 0.25% to 40%, preferably from about 0.5% to about 30% of a risedronate active ingredient and from about 60% to about 97%, preferably from about 70% to about 99.5% of pharmaceutically-acceptable excipients.
- safe and effective amount means an amount of a compound or composition high enough to significantly positively modify the symptoms and/or condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment.
- the safe and effective amount of active ingredient for use in the method of the invention herein will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, the particular active ingredient being employed, the particular pharmaceutically-acceptable excipients utilized, and like factors within the knowledge and expertise of the attending physician.
- risedronate active ingredient includes the risedronate, risedronate salts, and risedronate esters or any mixture thereof. Any pharmaceutically-acceptable, non-toxic salt or ester of risedronate may be used as the risedronate active ingredient in the dosage forms of the present invention.
- the salts of risedronate may be acid addition salts, in particular for risedronate the hydrochloride, but any pharmaceutically-acceptable, non-toxic organic or inorganic acid salt may be used.
- salts formed with the phosphonic acid group may be used, including, but not limited to alkali metal salts (K, Na) and alkaline earth metal salts (Ca, Mg) the Ca and Na salts being preferred.
- esters of bisphosphonate which are suitable for use as the active ingredient herein are straight chain or branched chain C 1 -C 18 alkyl esters, including, but not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, amyl, hexyl, heptyl, octyl, nonyl, decyl, lauryl, myristyl, cetyl, and stearyl; straight chain or branched C 2 -C 18 alkenyl, esters, including but not limited to vinyl, alkyl, undecenyl, and linolenyl; C 3 -C 8 cycloalkyl esters, including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl; aryl ester, including, but
- pharmaceutically-acceptable excipients includes any physiologically inert, pharmacologically inactive material known to one skilled in the art, which is compatible with the physical and chemical characteristics of the particular active ingredient selected for use.
- Pharmaceutically-acceptable excipients include, but are not limited to, polymers, resins, plasticizers, fillers, lubricants, binders, disintegrants, solvents, co-solvents, buffer systems, surfactants, preservatives, sweetening agents, flavoring agents, pharmaceutical grade dyes and pigments. All or part of the pharmaceutically-acceptable excipients contained in the pharmaceutical compositions described herein is used to make the film coating which is to be utilized in the novel oral dosage forms described herein.
- oral dosage form means any pharmaceutical composition intended to be administer to the stomach of an individual via the mouth of said individual
- pharmaceutically-acceptable excipients include, but are not limited to polymers, resins, plasticizers, fillers, lubricants, binders, disintegrants, solvents, co-solvents, surfactants, preservatives, sweetener agents, flavoring agents, buffer systems, pharmaceutical-grade dyes and pigments.
- the preferred solvent is water.
- Flavoring agents among those useful herein include those described in Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, 1990, pp. 1288-1300, incorporated by reference herein.
- Dyes, or pigments among those useful herein include those described in Handbook of Pharmaceutical Excipients, Second Edition pp. 126-134, 1994 by the American Pharmaceutical Association & the Pharmaceutical Press, incorporated by reference herein.
- Preferred co-solvents include, but are not limited to, ethanol, glycerin, propylene glycol, polyethylene glycol.
- Preferred buffer systems include, but are not limited to potassium acetate, boric carbonic, phosphoric, succinic, malic, tartaric, citric, acetic, benzoic, lactic, glyceric, gluconic, glutaric and glutamic. Particularly preferred are phosphoric, tartaric, citric, and potassium acetate.
- Preferred surfactants include, but are not limited to, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene monoalkyl ethers, sucrose monoesters and lanolin esters and ethers.
- Preferred preservatives include, but are not limited to, phenol, alkyl esters of parahydroxybenzoic acid, benzoic acid and the salts thereof, boric acid and the salts thereof, sorbic acid and the salts thereof, chorbutanol, benzyl alcohol, thimerosal, nitromersol, benzalkonium chloride, cetylpyridinium chloride, methyl paraben, and propyl paraben.
- Particularly preferred are the salts of benzoic acid, cetylpyridinium chloride, methyl paraben and propyl paraben.
- Preferred sweeteners include, but are not limited to, sucrose, glucose, saccharin, and aspartame. Particularly preferred are sucrose and saccharin.
- Preferred binders include, but are not limited to methycellulose, sodium carboxymethycellulose, hydroxypropylmethylcellulose, carbomer, povidone, acacia, guar gum, xanthan gum and tragacanth. Particularly preferred are methycellulose, carbomer, xanthan gum, guar gum, povidone and sodium carboxymethycellulose.
- Preferred fillers include, but are not limited to lactose, sucrose, maltodextrin, mannitol, starch, and microcrystalline cellulose.
- Preferred plasticizers include, but are not limited to polyethylene glycol, propylene glycol, dibutyl phthalate, and castor oil, acetylated monoglycerides, and triacetin.
- Preferred lubricants include, but are not limited to, magnesium stearate, stearic acid, and talc.
- Preferred disintegrants include, but are not limited to, crospovidone, sodium carboxymethyl starch, sodium starch glycolate, sodium carboxymethyl cellulose, alginic acid, clays, and ion exchange resins.
- Preferred polymers include but are not limited to hydroxypropylmethylcellulose (HPMC) alone and/or in combination with hydroxypropylcellulose (HPC), carboxymethylcellulose, acrylic resins such as Eudragit® RL30D, manufactured by Rohm Pharma GmbH Weiderstadt, West Germany, methylcellulose, ethylcellulose, and polyvinylpyrrolidone or other commercially available film-coating preparations such as Dri-Klear, manufactured by Crompton & Knowles Corp., Mahwah, N.J. or Opadry manufactured by Colorcon, West Point, Pa.
- HPMC hydroxypropylmethylcellulose
- HPC hydroxypropylcellulose
- carboxymethylcellulose acrylic resins such as Eudragit® RL30D, manufactured by Rohm Pharma GmbH Weiderstadt, West Germany
- methylcellulose, ethylcellulose and polyvinylpyrrolidone or other commercially available film-coating preparations
- Dri-Klear manufactured by Crompton & Knowles Corp., Mahwah
- formulations which may be used to administer the bisphosphonate active ingredient.
- Such formulations include but are not limited to gel formulations as disclosed in WO97/29754 and EP 0 407 344; effervescent formulations as disclosed in WO97/44017; iontophoretic formulations as disclosed in U.S. Pat. No. 5,730,715; and transdermal formulations as disclosed in EP 0 407 345.
- compositions of the present invention allow for greater flexibility in dosage administration and dosing intervals.
- the compositions of the present invention may be dosed daily, weekly, biweekly or monthly.
- the safe and effective amount will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of treatment, and the nature of concurrent therapy.
Abstract
Description
TABLE 1 | |||||
Weight | |||||
of Water | IPA | ||||
(X = | Addition | % | |||
Ex- | weight of | Weight of | Temp | Cooling Ramp | H2O |
ample | compound 2) | isopropanol | (° C.) | (° C.) | KF |
1 | 8.72X | 2.94X | 70 | 70 hold | 5.7 |
2 | 22X | 160X@0° C. | 70 | 70-0 in 2 min. | 5.9 |
Quench | |||||
3 | 7.2X | 1.08X | 75 | 75-60 in 4 hrs | 9.6 |
60-25 in 2 hrs. | |||||
4 | 9X | 1.26X | 75 | 75-60 in 4 hrs | 11.4 |
60-25 in 2 hrs | |||||
5 | 8.2X | 0.9X | 60 | 60 hold 4 hrs. | 12.3 |
60-25 in 2 hrs. | |||||
6 | 9.5X | 1.05X | 60 | 60-25 in 2 hrs | 13.0 |
7 | 8.2X | 1.39X | 60 | 60 hold 4 hrs. | 13.0 |
60-25 in 2 hrs. | |||||
8 | 8.2X | 1.15X | 60 | 60-25 in 2 hrs | 13.1 |
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/771,825 US6410520B2 (en) | 2000-02-01 | 2001-01-29 | Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17950500P | 2000-02-01 | 2000-02-01 | |
US09/771,825 US6410520B2 (en) | 2000-02-01 | 2001-01-29 | Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020002282A1 US20020002282A1 (en) | 2002-01-03 |
US6410520B2 true US6410520B2 (en) | 2002-06-25 |
Family
ID=22656866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/771,825 Expired - Lifetime US6410520B2 (en) | 2000-02-01 | 2001-01-29 | Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate |
Country Status (33)
Country | Link |
---|---|
US (1) | US6410520B2 (en) |
EP (1) | EP1252170B2 (en) |
JP (5) | JP2003521532A (en) |
KR (1) | KR100549038B1 (en) |
CN (1) | CN1183148C (en) |
AR (1) | AR030187A1 (en) |
AT (1) | ATE273984T1 (en) |
AU (1) | AU784307B2 (en) |
BR (1) | BRPI0107921B8 (en) |
CA (1) | CA2399976C (en) |
CO (1) | CO5271720A1 (en) |
CZ (1) | CZ303400B6 (en) |
DE (1) | DE60104978T3 (en) |
DK (1) | DK1252170T4 (en) |
ES (1) | ES2225481T5 (en) |
HK (1) | HK1051046B (en) |
HU (1) | HU230494B1 (en) |
IL (2) | IL150511A0 (en) |
MA (1) | MA25654A1 (en) |
MX (1) | MXPA02007417A (en) |
MY (1) | MY119968A (en) |
NO (1) | NO329923B1 (en) |
NZ (1) | NZ519966A (en) |
PE (1) | PE20011061A1 (en) |
PL (1) | PL207589B1 (en) |
PT (1) | PT1252170E (en) |
RU (1) | RU2236415C2 (en) |
SA (1) | SA01220066B1 (en) |
SK (1) | SK287884B6 (en) |
TR (1) | TR200402435T4 (en) |
TW (1) | TWI310769B (en) |
WO (1) | WO2001056983A2 (en) |
ZA (1) | ZA200205090B (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030195170A1 (en) * | 2002-04-11 | 2003-10-16 | Judith Aronhime | Novel polymorphs and pseudopolymorphs of risedronate sodium |
US20040192655A1 (en) * | 2003-01-17 | 2004-09-30 | Revital Lifshitz-Liron | Risedronate sodium having a very low content of iron |
US20050026869A1 (en) * | 2003-07-30 | 2005-02-03 | The Procter & Gamble Company | Process for controlling crystal structure of risedronate |
US20050260272A1 (en) * | 2004-05-05 | 2005-11-24 | Alkermes Controlled Therapeutics, Inc. | Method of forming microparticles that include a bisphosphonate and a polymer |
US20060079487A1 (en) * | 2004-10-08 | 2006-04-13 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
WO2006051553A1 (en) * | 2004-11-09 | 2006-05-18 | Jubilant Organosys Limited | Process for preparing a pure polymorphic form of 3-pyridyl-1-hydroxyethylidine-1,1-bisphosphonic acid sodium salt |
US20060122395A1 (en) * | 2003-01-28 | 2006-06-08 | Jozsef Neu | Industrial process for the synthesis of 2-substituted 1-(hydroxy-ethylidene)-1,1-bisphosfi- conic acids of high purity and the salts thereof |
WO2006134603A1 (en) | 2005-06-13 | 2006-12-21 | Jubilant Organosys Limited | Process for producing bisphosphonic acids and forms thereof |
US20070142332A1 (en) * | 2004-02-26 | 2007-06-21 | Zentiva , A.S. | Amorphous forms of risedronate monosodium |
KR100775440B1 (en) | 2006-12-20 | 2007-11-12 | 동우신테크 주식회사 | Process for preparing sodium risedronate hemipentahydrate |
WO2007083243A3 (en) * | 2006-01-20 | 2007-11-29 | Aurobindo Pharma Ltd | An improved process for the preparation of risedronate sodium hemi-pentahydrate |
US20070275931A1 (en) * | 2006-03-17 | 2007-11-29 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods |
EP1923052A1 (en) | 2002-04-11 | 2008-05-21 | Teva Pharmaceutical Industries Ltd | Novel polymorphs and pseudopolymorphs of risedronate sodium |
US20080194525A1 (en) * | 2005-05-06 | 2008-08-14 | Jordi Puig Serrano | Process of Making Geminal Bisphosphonic Acids and Pharmaceutically Acceptable Salts and/or Hydrates Thereof |
US20080255070A1 (en) * | 2004-10-08 | 2008-10-16 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate Compounds and Methods with Enhanced Potency for Multiple Targets including FPPS, GGPPS, AND DPPS |
DE102007030370A1 (en) | 2007-06-29 | 2009-01-02 | Ratiopharm Gmbh | Acetic acid-solvate of risedronate, useful e.g. to treat or prevent bone resorption disorder, tumors or a disturbed calcium- or phosphate-metabolism |
US20090149427A1 (en) * | 2005-09-30 | 2009-06-11 | Pliva Hrvatska D.O.O. | Pharmaceutically acceptable salts and hydrates of risedronic acid |
US20090176913A1 (en) * | 2006-05-09 | 2009-07-09 | Adeka Corporation | Polyester resin composition |
US20090198062A1 (en) * | 2006-07-03 | 2009-08-06 | Gore Vinayak G | Novel process |
US20090281320A1 (en) * | 2004-12-28 | 2009-11-12 | Zaklady Farmaceutyczne Polpharma Sa | Process for the preparation of [1-hydroxy-2-(3-pyridinyl)ethylidene] bisphosphonic acid and hemipentahydrate monosodium salt thereof |
US20100121066A1 (en) * | 2007-06-20 | 2010-05-13 | Ankush Tavhare M | Novel Process For Preparing Risedronic Acid |
US20100317859A1 (en) * | 2007-05-16 | 2010-12-16 | Actavis Group Ptc Ehf | Process for the Preparation of Risedronate Sodium |
EP2269584A1 (en) | 2004-05-24 | 2011-01-05 | Warner Chilcott Company, LLC | Enteric solid oral dosage form of a bisphosphonate containing a chelating agent |
US8076483B2 (en) | 2006-05-11 | 2011-12-13 | M/S. Ind Swift Laboratories Limited | Process for the preparation of pure risedronic acid or salts |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20011061A1 (en) * | 2000-02-01 | 2001-11-20 | Procter & Gamble | SELECTIVE CRYSTALLIZATION OF 3-PYRIDYL-1-HYDROXY-ETHYLIDEN-1,1-BISPHOSPHONIC SODIUM ACID AS HEMIPENTAHYDRATE OR MONOHYDRATE |
CZ293349B6 (en) | 2002-10-25 | 2004-04-14 | Léčiva, A.S. | Novel crystalline form of 3-pyridyl-1-hydroxyethylidene-1,1-bisphopshonoc acid sodium salt |
CZ298639B6 (en) * | 2004-02-05 | 2007-12-05 | Zentiva, A. S. | Crystalline form of monosodium risedronate |
AR054673A1 (en) * | 2005-07-28 | 2007-07-11 | Gador Sa | A CRYSTAL FORM OF THE ZOLEDRONIC ACID, A PROCESS FOR THEIR OBTAINING AND THE PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT |
EP1775302A1 (en) * | 2005-10-11 | 2007-04-18 | Sandoz A/S | Method for preparing crystalline sodium risedronate |
WO2007042048A2 (en) * | 2005-10-11 | 2007-04-19 | Sandoz A/S | Method for preparing crystalline sodium risedronate |
WO2008065542A2 (en) * | 2006-09-22 | 2008-06-05 | Orchid Chemicals & Pharmaceuticals Ltd. | An improved process for the preparation of risedronate sodium |
WO2008044245A2 (en) * | 2006-10-10 | 2008-04-17 | Matrix Laboratories Ltd | A process for the preparation of risedronate sodium hemipentahydrate |
KR100828705B1 (en) | 2006-12-04 | 2008-05-09 | 씨제이제일제당 (주) | Method for preparing risedronate sodium hydrate |
KR100798855B1 (en) * | 2007-02-14 | 2008-01-28 | 주식회사 엔지켐 | Method for preparing sodium risedronate hemipentahydrate |
KR100812528B1 (en) * | 2007-04-12 | 2008-03-12 | 보령제약 주식회사 | The selectively crystallizing method of hemipentahydrate of risedronate sodium salt |
KR100925835B1 (en) * | 2007-12-07 | 2009-11-06 | 동우신테크 주식회사 | Process for preparing Risedronate sodium as anhydrous and hydrate forms |
KR101010062B1 (en) | 2008-04-11 | 2011-01-21 | 주식회사 대희화학 | Process for preparing Crystalline form of Risedronate monosodium monohydrate by evaporating crystallization |
JP2013510097A (en) * | 2009-11-03 | 2013-03-21 | リウ、リー | Tanshinone IIA sodium sulfonate hydrate and its preparation and use |
ES2754480T3 (en) * | 2015-07-08 | 2020-04-17 | Daiichi Sankyo Co Ltd | Pyrido-oxazinone derivatives as TNAP inhibitors |
KR102368241B1 (en) | 2017-06-06 | 2022-02-28 | 미쯔비시 케미컬 주식회사 | Polyorganosiloxane-containing graft copolymer, thermoplastic resin composition and molded article |
Citations (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4054598A (en) | 1975-08-01 | 1977-10-18 | Henkel & Cie Gmbh | 1-Hydroxy-3-amino-alkane-1,1-diphosphonic acids and salts |
JPS5598193A (en) | 1979-01-22 | 1980-07-25 | Nissan Chem Ind Ltd | Methylenediphosphonic acid derivative and herbicide comprising it as active constituent |
US4267108A (en) | 1977-10-07 | 1981-05-12 | Henkel Kommanditgesellschaft Auf Aktien | Hydroxyalkane diphosphonic acids |
US4304734A (en) | 1980-10-16 | 1981-12-08 | Vysoka Skola Chemicko-Technologicka | 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof |
US4327039A (en) | 1979-10-27 | 1982-04-27 | Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) | Process for the production of 3-amino-1-hydroxypropane-1,1-diphosphonic acid |
US4330537A (en) | 1977-12-07 | 1982-05-18 | The Procter & Gamble Company | Compositions for inhibiting mobilization of calcium phosphate in animal tissue |
EP0082472A2 (en) | 1981-12-23 | 1983-06-29 | Henkel Kommanditgesellschaft auf Aktien | Process for the preparation of 3-amino-1-hydroxypropane-1,1-diphosphonic acid |
US4407761A (en) | 1980-04-28 | 1983-10-04 | Henkel Kommanditgesellschaft Auf Aktien | Process for the production of ω-amino-1-hydroxyalkylidene-1,1-bisphosphonic acid |
US4447256A (en) | 1977-07-20 | 1984-05-08 | Nissan Chemical Industries, Ltd. | N-(Unsubstituted or substituted pyridyl)aminomethylene-diphosphonic acids, herbicidal compositions containing same, their use for herbicides, and process for preparing same |
US4621077A (en) | 1982-04-15 | 1986-11-04 | Istituto Gentili S.P.A. | Pharmacologically active biphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom |
US4705651A (en) | 1984-10-29 | 1987-11-10 | Istituto Gentili S.P.A. | Process for the preparation of diphosphonic acids |
US4719203A (en) | 1985-11-13 | 1988-01-12 | Boehringer Mannheim Gmbh | Diphosphonic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
EP0252505A1 (en) | 1986-07-11 | 1988-01-13 | Roche Diagnostics GmbH | 1-Hydroxy-3-(N-methyl-N-propyl amino)propane-1,1-diphosphonic acid, process for its preparation and medicines containing this compound |
BE1000075A4 (en) | 1987-01-13 | 1988-02-02 | Inst Khim Kinetiki I Gorenia S | METHOD FOR OBTAINING OF ACID alkylidene-I, I-diphosphonic FUNCTIONALLY SUBSTITUTED I AND THEIR MIXTURES. |
US4777163A (en) | 1986-08-01 | 1988-10-11 | Boehringer Mannheim Gmbh | Diphosphonate derivatives, pharmaceutical compositions and methods of use for calcium disturbances |
US4812316A (en) | 1985-10-15 | 1989-03-14 | Eurand Italia S.P.A. | Process for the preparation of stabilized isosorbide-5-mononitrate tablets, being also of sustained release, and formulations thus obtained |
US4939130A (en) | 1986-11-21 | 1990-07-03 | Ciba-Geigy Corporation | Substituted alkanediphosphonic acids and pharmaceutical use |
US5002937A (en) | 1988-07-05 | 1991-03-26 | Boehringer Mannheim Gmbh | Diphosphonic acid compounds and use for calcium metabolism disorders |
US5035898A (en) | 1987-11-27 | 1991-07-30 | Schering Corporation | Potassium/magnesium supplement |
US5039819A (en) | 1990-09-18 | 1991-08-13 | Merck & Co., Inc. | Diphosphonate intermediate for preparing an antihypercalcemic agent |
US5049663A (en) | 1986-03-24 | 1991-09-17 | Nippon Kayaku Kabushiki Kaisha | Process for producing 1-β-D-arabinofuranosylcytosine-5'-stearylphosphate monosodium salt and monohydrate thereof |
US5068440A (en) | 1985-12-17 | 1991-11-26 | Boots Company, Plc | Process for the manufacture of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate |
US5091525A (en) | 1987-10-07 | 1992-02-25 | Eli Lilly And Company | Monohydrate and DMF solvates of a new carbacephem antibiotic |
US5110807A (en) | 1988-12-01 | 1992-05-05 | Ciba-Geigy Corporation | Araliphatylaminoalkanediphosphonic acids |
EP0494844A1 (en) | 1991-01-08 | 1992-07-15 | ISTITUTO GENTILI S.p.A. | Process for the preparation of diphosphonic acids and salts thereof |
US5206253A (en) | 1989-05-26 | 1993-04-27 | Boehringer Mannheim, Gmbh | Disphosphonic acid derivatives, processes for their production and pharmaceutical preparations containing these compounds |
US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5317015A (en) | 1992-05-01 | 1994-05-31 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Azacyclic bisphosphonates as anticholesterolemic agents |
US5354760A (en) | 1991-04-02 | 1994-10-11 | Novo Nordisk A/S | Crystalline Tiagabine monohydrate, its preparation and use |
WO1995006052A1 (en) | 1993-08-25 | 1995-03-02 | Merck & Co., Inc. | Process for producing n-amino-1-hydroxy-alkyl-idene-1,1-bisphosphonic acids |
US5405994A (en) | 1992-08-05 | 1995-04-11 | Sanofi | Disodium 4-chlorophenylthiomethylenebisphosphonate monohydrate, its preparation and pharmaceutical compositions in which it is present |
US5480875A (en) | 1992-06-23 | 1996-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative |
US5525354A (en) | 1992-04-24 | 1996-06-11 | Leiras Oy | Pharmaceutical preparation and process for its manufacture |
US5545737A (en) | 1990-03-01 | 1996-08-13 | Daiichi Pharmaceutical Co., Ltd. | Process for selectively producing an (S)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7h-pyrido (1,2,3, -de) (1,4) benzoxazine-6-carboxylic acid hemihydrate or monohydrate |
WO1996033199A1 (en) | 1995-04-20 | 1996-10-24 | Merck & Co., Inc. | Process for making 1-hydroxybisphosphonates |
US5580977A (en) | 1995-03-01 | 1996-12-03 | Eli Lilly And Company | Process for preparing loracarbef monohydrate |
US5583122A (en) | 1984-12-21 | 1996-12-10 | The Procter & Gamble Company | Pharmaceutical compositions containing geminal diphosphonates |
US5602115A (en) | 1990-08-21 | 1997-02-11 | The Upjohn Company | Bisphosphonic acid derivatives as anti-arthritic agents |
GB2316945A (en) | 1996-09-03 | 1998-03-11 | Dong Kook Pharm Co Ltd | Preparation of 3-amino-1-hydroxypropane-1,1-diphosphonic acid from N-protected beta-alanine using phosphorous acid and a phosphorus chloride |
US5760009A (en) | 1993-04-28 | 1998-06-02 | Pfizer Inc. | Spirostanyl glycosidal crystalline monohydrate |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3428524A1 (en) * | 1984-08-02 | 1986-02-13 | Boehringer Mannheim Gmbh, 6800 Mannheim | NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
PH27078A (en) * | 1984-12-21 | 1993-02-01 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonates |
MX21452A (en) | 1989-07-07 | 1994-01-31 | Ciba Geigy Ag | PHARMACEUTICAL PREPARATIONS THAT ARE TOPICALLY ADMINISTERED. |
MX21453A (en) | 1989-07-07 | 1994-01-31 | Ciba Geigy Ag | PHARMACEUTICAL PREPARATIONS THAT ARE TOPICALLY ADMINISTERED. |
ES2149781T3 (en) * | 1991-11-22 | 2000-11-16 | Procter & Gamble Pharma | RISEDRONATE COMPOSITIONS OF DELAYED RELEASE. |
TW257765B (en) * | 1993-08-25 | 1995-09-21 | Merck & Co Inc | |
US5656288A (en) * | 1995-06-08 | 1997-08-12 | Sanofi Winthrop, Inc. | Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions |
EP0886521B1 (en) | 1996-02-14 | 2003-05-21 | Itzhak Binderman | Topical bisphosphonates for prevention of bone resorption |
DE69726879T2 (en) | 1996-05-17 | 2004-10-14 | Merck & Co., Inc. | BIPHOSPHONATE FORMULATION WITH EFFECT |
US5730715A (en) | 1996-06-14 | 1998-03-24 | Becton Dickinson And Company | Method for the iontophoretic administration of bisphosphonates |
WO1998056360A2 (en) * | 1997-06-11 | 1998-12-17 | The Procter & Gamble Company | Film-coated tablet for improved upper gastrointestinal tract safety |
PT891979E (en) * | 1997-07-15 | 2005-02-28 | Gador Sa | A NON-DIMETHYL-3-AMINO-1-HYDROXYPROPAN-1,1-DIFFOSPHONIC ACID MONYODODATE SALT CRYSTALLINE FORM AND THE PROCEDURE FOR PREPARATION |
US6432932B1 (en) * | 1997-07-22 | 2002-08-13 | Merck & Co., Inc. | Method for inhibiting bone resorption |
JP2002518457A (en) * | 1998-06-24 | 2002-06-25 | メルク エンド カムパニー インコーポレーテッド | Compositions and methods for inhibiting bone resorption |
US20010044427A1 (en) * | 1999-12-20 | 2001-11-22 | Sidney Mazel | Pharmaceutical kit |
PE20011061A1 (en) * | 2000-02-01 | 2001-11-20 | Procter & Gamble | SELECTIVE CRYSTALLIZATION OF 3-PYRIDYL-1-HYDROXY-ETHYLIDEN-1,1-BISPHOSPHONIC SODIUM ACID AS HEMIPENTAHYDRATE OR MONOHYDRATE |
-
2001
- 2001-01-29 PE PE2001000096A patent/PE20011061A1/en active IP Right Grant
- 2001-01-29 US US09/771,825 patent/US6410520B2/en not_active Expired - Lifetime
- 2001-01-30 CO CO01006628A patent/CO5271720A1/en not_active Application Discontinuation
- 2001-01-30 MY MYPI20010386A patent/MY119968A/en unknown
- 2001-01-31 AR ARP010100430A patent/AR030187A1/en not_active Application Discontinuation
- 2001-02-01 BR BRPI0107921A patent/BRPI0107921B8/en not_active IP Right Cessation
- 2001-02-01 RU RU2002123369/04A patent/RU2236415C2/en active
- 2001-02-01 EP EP01906880.8A patent/EP1252170B2/en not_active Expired - Lifetime
- 2001-02-01 SK SK1100-2002A patent/SK287884B6/en not_active IP Right Cessation
- 2001-02-01 MX MXPA02007417A patent/MXPA02007417A/en active IP Right Grant
- 2001-02-01 IL IL15051101A patent/IL150511A0/en active IP Right Review Request
- 2001-02-01 NZ NZ519966A patent/NZ519966A/en not_active IP Right Cessation
- 2001-02-01 WO PCT/US2001/003336 patent/WO2001056983A2/en active IP Right Grant
- 2001-02-01 CA CA002399976A patent/CA2399976C/en not_active Expired - Lifetime
- 2001-02-01 ES ES01906880.8T patent/ES2225481T5/en not_active Expired - Lifetime
- 2001-02-01 KR KR1020027009790A patent/KR100549038B1/en active IP Right Review Request
- 2001-02-01 AT AT01906880T patent/ATE273984T1/en active
- 2001-02-01 PT PT01906880T patent/PT1252170E/en unknown
- 2001-02-01 CZ CZ20022516A patent/CZ303400B6/en not_active IP Right Cessation
- 2001-02-01 CN CNB018042996A patent/CN1183148C/en not_active Expired - Lifetime
- 2001-02-01 JP JP2001556833A patent/JP2003521532A/en active Pending
- 2001-02-01 DK DK01906880.8T patent/DK1252170T4/en active
- 2001-02-01 PL PL357097A patent/PL207589B1/en unknown
- 2001-02-01 AU AU34736/01A patent/AU784307B2/en not_active Expired
- 2001-02-01 TR TR2004/02435T patent/TR200402435T4/en unknown
- 2001-02-01 DE DE60104978.0T patent/DE60104978T3/en not_active Expired - Lifetime
- 2001-02-01 HU HU0204203A patent/HU230494B1/en unknown
- 2001-02-05 TW TW090102064A patent/TWI310769B/en not_active IP Right Cessation
- 2001-04-18 SA SA01220066A patent/SA01220066B1/en unknown
-
2002
- 2002-06-25 ZA ZA200205090A patent/ZA200205090B/en unknown
- 2002-07-01 IL IL150511A patent/IL150511A/en unknown
- 2002-07-31 NO NO20023645A patent/NO329923B1/en not_active IP Right Cessation
- 2002-08-01 MA MA26758A patent/MA25654A1/en unknown
-
2003
- 2003-03-13 HK HK03101833.6A patent/HK1051046B/en not_active IP Right Cessation
-
2010
- 2010-02-15 JP JP2010030081A patent/JP5405343B2/en not_active Expired - Lifetime
-
2012
- 2012-08-13 JP JP2012179449A patent/JP5859930B2/en not_active Expired - Lifetime
-
2014
- 2014-08-13 JP JP2014164982A patent/JP5900553B2/en not_active Expired - Lifetime
-
2015
- 2015-09-14 JP JP2015181140A patent/JP2016028083A/en active Pending
Patent Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4054598A (en) | 1975-08-01 | 1977-10-18 | Henkel & Cie Gmbh | 1-Hydroxy-3-amino-alkane-1,1-diphosphonic acids and salts |
US4447256A (en) | 1977-07-20 | 1984-05-08 | Nissan Chemical Industries, Ltd. | N-(Unsubstituted or substituted pyridyl)aminomethylene-diphosphonic acids, herbicidal compositions containing same, their use for herbicides, and process for preparing same |
US4267108A (en) | 1977-10-07 | 1981-05-12 | Henkel Kommanditgesellschaft Auf Aktien | Hydroxyalkane diphosphonic acids |
US4330537A (en) | 1977-12-07 | 1982-05-18 | The Procter & Gamble Company | Compositions for inhibiting mobilization of calcium phosphate in animal tissue |
JPS5598193A (en) | 1979-01-22 | 1980-07-25 | Nissan Chem Ind Ltd | Methylenediphosphonic acid derivative and herbicide comprising it as active constituent |
US4327039A (en) | 1979-10-27 | 1982-04-27 | Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) | Process for the production of 3-amino-1-hydroxypropane-1,1-diphosphonic acid |
US4407761A (en) | 1980-04-28 | 1983-10-04 | Henkel Kommanditgesellschaft Auf Aktien | Process for the production of ω-amino-1-hydroxyalkylidene-1,1-bisphosphonic acid |
US4304734A (en) | 1980-10-16 | 1981-12-08 | Vysoka Skola Chemicko-Technologicka | 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof |
EP0082472A2 (en) | 1981-12-23 | 1983-06-29 | Henkel Kommanditgesellschaft auf Aktien | Process for the preparation of 3-amino-1-hydroxypropane-1,1-diphosphonic acid |
US4621077A (en) | 1982-04-15 | 1986-11-04 | Istituto Gentili S.P.A. | Pharmacologically active biphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom |
US4705651A (en) | 1984-10-29 | 1987-11-10 | Istituto Gentili S.P.A. | Process for the preparation of diphosphonic acids |
US5583122A (en) | 1984-12-21 | 1996-12-10 | The Procter & Gamble Company | Pharmaceutical compositions containing geminal diphosphonates |
US4812316A (en) | 1985-10-15 | 1989-03-14 | Eurand Italia S.P.A. | Process for the preparation of stabilized isosorbide-5-mononitrate tablets, being also of sustained release, and formulations thus obtained |
US4719203A (en) | 1985-11-13 | 1988-01-12 | Boehringer Mannheim Gmbh | Diphosphonic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
US5068440A (en) | 1985-12-17 | 1991-11-26 | Boots Company, Plc | Process for the manufacture of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate |
US5049663A (en) | 1986-03-24 | 1991-09-17 | Nippon Kayaku Kabushiki Kaisha | Process for producing 1-β-D-arabinofuranosylcytosine-5'-stearylphosphate monosodium salt and monohydrate thereof |
EP0252505A1 (en) | 1986-07-11 | 1988-01-13 | Roche Diagnostics GmbH | 1-Hydroxy-3-(N-methyl-N-propyl amino)propane-1,1-diphosphonic acid, process for its preparation and medicines containing this compound |
US4927814A (en) | 1986-07-11 | 1990-05-22 | Boehringer Mannheim Gmbh | Diphosphonate derivatives, pharmaceutical compositions and methods of use |
US4942157A (en) | 1986-07-11 | 1990-07-17 | Boehringer Mannheim Gmbh | 1-hydroxy-3-(N-methyl-N-propylamino)propane-1,1-diphosphonic acid, pharmaceutical compositions and methods of use |
US4777163A (en) | 1986-08-01 | 1988-10-11 | Boehringer Mannheim Gmbh | Diphosphonate derivatives, pharmaceutical compositions and methods of use for calcium disturbances |
US4939130A (en) | 1986-11-21 | 1990-07-03 | Ciba-Geigy Corporation | Substituted alkanediphosphonic acids and pharmaceutical use |
BE1000075A4 (en) | 1987-01-13 | 1988-02-02 | Inst Khim Kinetiki I Gorenia S | METHOD FOR OBTAINING OF ACID alkylidene-I, I-diphosphonic FUNCTIONALLY SUBSTITUTED I AND THEIR MIXTURES. |
US5091525A (en) | 1987-10-07 | 1992-02-25 | Eli Lilly And Company | Monohydrate and DMF solvates of a new carbacephem antibiotic |
US5035898A (en) | 1987-11-27 | 1991-07-30 | Schering Corporation | Potassium/magnesium supplement |
US5002937A (en) | 1988-07-05 | 1991-03-26 | Boehringer Mannheim Gmbh | Diphosphonic acid compounds and use for calcium metabolism disorders |
US5110807A (en) | 1988-12-01 | 1992-05-05 | Ciba-Geigy Corporation | Araliphatylaminoalkanediphosphonic acids |
US5206253A (en) | 1989-05-26 | 1993-04-27 | Boehringer Mannheim, Gmbh | Disphosphonic acid derivatives, processes for their production and pharmaceutical preparations containing these compounds |
US5545737A (en) | 1990-03-01 | 1996-08-13 | Daiichi Pharmaceutical Co., Ltd. | Process for selectively producing an (S)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7h-pyrido (1,2,3, -de) (1,4) benzoxazine-6-carboxylic acid hemihydrate or monohydrate |
US5602115A (en) | 1990-08-21 | 1997-02-11 | The Upjohn Company | Bisphosphonic acid derivatives as anti-arthritic agents |
US5039819A (en) | 1990-09-18 | 1991-08-13 | Merck & Co., Inc. | Diphosphonate intermediate for preparing an antihypercalcemic agent |
EP0494844A1 (en) | 1991-01-08 | 1992-07-15 | ISTITUTO GENTILI S.p.A. | Process for the preparation of diphosphonic acids and salts thereof |
US5354760A (en) | 1991-04-02 | 1994-10-11 | Novo Nordisk A/S | Crystalline Tiagabine monohydrate, its preparation and use |
US5525354A (en) | 1992-04-24 | 1996-06-11 | Leiras Oy | Pharmaceutical preparation and process for its manufacture |
US5317015A (en) | 1992-05-01 | 1994-05-31 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Azacyclic bisphosphonates as anticholesterolemic agents |
US5480875A (en) | 1992-06-23 | 1996-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative |
US5405994A (en) | 1992-08-05 | 1995-04-11 | Sanofi | Disodium 4-chlorophenylthiomethylenebisphosphonate monohydrate, its preparation and pharmaceutical compositions in which it is present |
US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5760009A (en) | 1993-04-28 | 1998-06-02 | Pfizer Inc. | Spirostanyl glycosidal crystalline monohydrate |
WO1995006052A1 (en) | 1993-08-25 | 1995-03-02 | Merck & Co., Inc. | Process for producing n-amino-1-hydroxy-alkyl-idene-1,1-bisphosphonic acids |
US5580977A (en) | 1995-03-01 | 1996-12-03 | Eli Lilly And Company | Process for preparing loracarbef monohydrate |
WO1996033199A1 (en) | 1995-04-20 | 1996-10-24 | Merck & Co., Inc. | Process for making 1-hydroxybisphosphonates |
GB2316945A (en) | 1996-09-03 | 1998-03-11 | Dong Kook Pharm Co Ltd | Preparation of 3-amino-1-hydroxypropane-1,1-diphosphonic acid from N-protected beta-alanine using phosphorous acid and a phosphorus chloride |
Non-Patent Citations (3)
Title |
---|
Ebetino et al., "Elucidation of a Pharmacophore for the Bisphosphonate Mechanism of Bone Antiresorptive Activity", Phosphorus, Sulfur, and Silicon, vol. 109-110, pp. 217-220, 1996. |
Ebetino et al., "Recent Work on the Synthesis of Phosphonate-Containing, Bone-Active Heterocycles", Heterocycles, vol. 30, No. 2, pp. 855-862, 1990. |
Nicholson et al., "A General Method of Preparation of Tetramethyl Alkyl-1-hydroxy-1,1-diphosphonates", J. Of Organic Chem., vol. 36, pp. 3843-3845, 1971. |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003086355A1 (en) * | 2002-04-11 | 2003-10-23 | Teva Pharmaceutical Indudstries, Ltd. | Novel polymorphs and pseudopolymorphs of risedronate sodium |
EP1923052A1 (en) | 2002-04-11 | 2008-05-21 | Teva Pharmaceutical Industries Ltd | Novel polymorphs and pseudopolymorphs of risedronate sodium |
US20030195170A1 (en) * | 2002-04-11 | 2003-10-16 | Judith Aronhime | Novel polymorphs and pseudopolymorphs of risedronate sodium |
US7358360B2 (en) * | 2003-01-17 | 2008-04-15 | Teva Pharmaceutical Industries Ltd. | Risedronate sodium having a very low content of iron |
US20040192655A1 (en) * | 2003-01-17 | 2004-09-30 | Revital Lifshitz-Liron | Risedronate sodium having a very low content of iron |
US7612229B2 (en) * | 2003-01-28 | 2009-11-03 | Richter Gedeon Vegyeszeti Gyar Rt. | Industrial process for the synthesis of 2-substituted 1-(hydroxy-ethylidene)-1,1-bisphosfi- conic acids of high purity and the salts thereof |
US20060122395A1 (en) * | 2003-01-28 | 2006-06-08 | Jozsef Neu | Industrial process for the synthesis of 2-substituted 1-(hydroxy-ethylidene)-1,1-bisphosfi- conic acids of high purity and the salts thereof |
US20050026869A1 (en) * | 2003-07-30 | 2005-02-03 | The Procter & Gamble Company | Process for controlling crystal structure of risedronate |
US7002014B2 (en) | 2003-07-30 | 2006-02-21 | The Procter & Gamble Company | Process for controlling crystal structure of risedronate |
US7618953B2 (en) * | 2004-02-26 | 2009-11-17 | Zentiva, A.S. | Amorphous forms of risedronate monosodium |
US20070142332A1 (en) * | 2004-02-26 | 2007-06-21 | Zentiva , A.S. | Amorphous forms of risedronate monosodium |
US20050260272A1 (en) * | 2004-05-05 | 2005-11-24 | Alkermes Controlled Therapeutics, Inc. | Method of forming microparticles that include a bisphosphonate and a polymer |
EP2269584A1 (en) | 2004-05-24 | 2011-01-05 | Warner Chilcott Company, LLC | Enteric solid oral dosage form of a bisphosphonate containing a chelating agent |
EP2283825A1 (en) | 2004-05-24 | 2011-02-16 | Warner Chilcott Company, LLC | Enteric solid oral dosage form of a bisphosphonate containing a chelating agent |
US20080318906A1 (en) * | 2004-10-08 | 2008-12-25 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
US8071573B2 (en) | 2004-10-08 | 2011-12-06 | The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
US7358361B2 (en) | 2004-10-08 | 2008-04-15 | The Board Of Trustees Of The University Of Illinois | Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
US20100316676A1 (en) * | 2004-10-08 | 2010-12-16 | Sanders John M | Bisphosphonate Compounds and Methods for Bone Resorption Diseases, Cancer, Bone Pain, Immune Disorders, and Infectious Diseases |
US20080255070A1 (en) * | 2004-10-08 | 2008-10-16 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate Compounds and Methods with Enhanced Potency for Multiple Targets including FPPS, GGPPS, AND DPPS |
US7745422B2 (en) | 2004-10-08 | 2010-06-29 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
US20060079487A1 (en) * | 2004-10-08 | 2006-04-13 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
US8012949B2 (en) | 2004-10-08 | 2011-09-06 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS |
US20080300408A1 (en) * | 2004-11-09 | 2008-12-04 | Jubilant Organosys Limited | Process for Preparing a Pure Polymorphic Form of 3-Pyridyl-1-Hydroxyethylidine-1, 1-Bisphosphonic Acid Sodium Salt |
WO2006051553A1 (en) * | 2004-11-09 | 2006-05-18 | Jubilant Organosys Limited | Process for preparing a pure polymorphic form of 3-pyridyl-1-hydroxyethylidine-1,1-bisphosphonic acid sodium salt |
US8450488B2 (en) * | 2004-12-28 | 2013-05-28 | Zaklady Farmaceutyczne Polpharma S.A. | Process for the preparation of [1-hydroxy-2-(3-pyridinyl)ethylidene] bisphosphonic acid and hemipentahydrate monosodium salt thereof |
US20090281320A1 (en) * | 2004-12-28 | 2009-11-12 | Zaklady Farmaceutyczne Polpharma Sa | Process for the preparation of [1-hydroxy-2-(3-pyridinyl)ethylidene] bisphosphonic acid and hemipentahydrate monosodium salt thereof |
US20080194525A1 (en) * | 2005-05-06 | 2008-08-14 | Jordi Puig Serrano | Process of Making Geminal Bisphosphonic Acids and Pharmaceutically Acceptable Salts and/or Hydrates Thereof |
US20090312551A1 (en) * | 2005-06-13 | 2009-12-17 | Satish Chandra Pandey | Process for producing biphosphonic acids and forms thereof |
US7872144B2 (en) | 2005-06-13 | 2011-01-18 | Jubilant Organosys Limited | Process for producing biphosphonic acids and forms thereof |
WO2006134603A1 (en) | 2005-06-13 | 2006-12-21 | Jubilant Organosys Limited | Process for producing bisphosphonic acids and forms thereof |
US20090149427A1 (en) * | 2005-09-30 | 2009-06-11 | Pliva Hrvatska D.O.O. | Pharmaceutically acceptable salts and hydrates of risedronic acid |
WO2007083243A3 (en) * | 2006-01-20 | 2007-11-29 | Aurobindo Pharma Ltd | An improved process for the preparation of risedronate sodium hemi-pentahydrate |
US7687482B2 (en) | 2006-03-17 | 2010-03-30 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods |
US20070275931A1 (en) * | 2006-03-17 | 2007-11-29 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods |
US20090176913A1 (en) * | 2006-05-09 | 2009-07-09 | Adeka Corporation | Polyester resin composition |
US8076483B2 (en) | 2006-05-11 | 2011-12-13 | M/S. Ind Swift Laboratories Limited | Process for the preparation of pure risedronic acid or salts |
US20090198062A1 (en) * | 2006-07-03 | 2009-08-06 | Gore Vinayak G | Novel process |
KR100775440B1 (en) | 2006-12-20 | 2007-11-12 | 동우신테크 주식회사 | Process for preparing sodium risedronate hemipentahydrate |
US20100317859A1 (en) * | 2007-05-16 | 2010-12-16 | Actavis Group Ptc Ehf | Process for the Preparation of Risedronate Sodium |
US20100121066A1 (en) * | 2007-06-20 | 2010-05-13 | Ankush Tavhare M | Novel Process For Preparing Risedronic Acid |
DE102007030370A1 (en) | 2007-06-29 | 2009-01-02 | Ratiopharm Gmbh | Acetic acid-solvate of risedronate, useful e.g. to treat or prevent bone resorption disorder, tumors or a disturbed calcium- or phosphate-metabolism |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6410520B2 (en) | Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate | |
EP1252169B1 (en) | Process for making geminal bisphosphonates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PROCTER & GAMBLE COMPANY, THE, OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CAZER, FREDERICK DANA;PARRY, GREGORY EUGENE;BILLINGS, DENNIS MICHAEL;AND OTHERS;REEL/FRAME:012450/0308 Effective date: 20010917 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: CREDIT SUISSE, CAYMAN ISLANDS BRANCH, AS ADMINISTR Free format text: SECURITY AGREEMENT;ASSIGNOR:WARNER CHILCOTT COMPANY, LLC;REEL/FRAME:023456/0052 Effective date: 20091030 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: WARNER CHILCOTT COMPANY, LLC,PUERTO RICO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PROCTER & GAMBLE COMPANY, THE;REEL/FRAME:023796/0417 Effective date: 20091030 Owner name: WARNER CHILCOTT COMPANY, LLC, PUERTO RICO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PROCTER & GAMBLE COMPANY, THE;REEL/FRAME:023796/0417 Effective date: 20091030 |
|
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: WARNER CHILCOTT COMPANY LLC, PUERTO RICO Free format text: RELEASE - REEL 023456, FRAME 0052;ASSIGNOR:CREDIT SUISSSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT;REEL/FRAME:026042/0046 Effective date: 20110317 |
|
AS | Assignment |
Owner name: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT, NO Free format text: SECURITY AGREEMENT;ASSIGNOR:WARNER CHILCOTT COMPANY LLC;REEL/FRAME:026064/0607 Effective date: 20110317 |
|
AS | Assignment |
Owner name: WARNER CHILCOTT COMPANY, LLC, NEW JERSEY Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:BANK OF AMERICA, N.A., AS COLLATERAL AGENT;REEL/FRAME:031531/0538 Effective date: 20131001 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED, IR Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WARNER CHILCOTT COMPANY, LLC;REEL/FRAME:040183/0129 Effective date: 20151231 |
|
AS | Assignment |
Owner name: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED, IR Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE US PATENT NO. 8,050,873 PREVIOUSLY RECORDED ON REEL 040183 FRAME 0129. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:WARNER CHILCOTT COMPANY, LLC;REEL/FRAME:045417/0593 Effective date: 20151231 |